Givebutter Campaign to Launch Today to Help Cover Start-Up Costs COLUMBUS, Ohio , Dec. 13, 2023 /PRNewswire/ -- Share Your Story Foundation – a non-profit organization that meets the practical needs of families affected by cancer – ...
PRINCETON, N.J. and SUZHOU, China , Dec. 13, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development ...
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63% overall response rate; responses ...
Study indicates clear route to market despite not meeting the primary endpoint of 6 months' overall response rate (ORR) in the entire population In a predefined subgroup of patients there was a doubling of ORR (51.9% vs 26.7% for ...
The collaboration will evaluate the ability of NeoImmuneTech's immune cell amplifier NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing. The combination potential of azer-cel and NT-I7 to increase ...
SHANGHAI and NANJING , China and SAN JOSE, Calif. , Dec. 11, 2023 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies ...
ConcertAI will invest in CancerLinQ to provide its members with upgraded quality reporting, industry-leading real-world data, and AI-powered solutions for accelerated clinical trials in a multi-year cooperation agreement with ASCO ...
Results Presented at the 2023 San Antonio Breast Cancer Symposium NEW YORK , Dec. 11, 2023 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform ...
SHANGHAI , Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that ...
Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli ...
Ex-cigarette smokers who use e-cigarettes or vaping devices may face a higher risk of lung cancer compared to those who don't vape ( ). “This is the first large ...
Immunotherapy, which aims to harness the immune system to combat cancer, has proven effective for about 20% of cancer patients. Notable progress has been made, particularly in treating lung cancer and melanoma . Inspired by the significant potential ...
Researchers at The Australian National University (ANU) have developed a new AI tool DEPLOY that quickly and accurately classifies brain tumors. Dr. Danh-Tai Hoang emphasizes that precise diagnosis and categorization of tumors are crucial for ...
Breast cancer remains the predominant cancer among women globally, with escalating rates prompting a pressing quest for novel modifiable risk factors. Recent findings propose a correlation between increased childhood adiposity and decreased breast ...
Researchers have unveiled a fresh understanding of the genetic pathway involved in childhood cancer , providing optimism for personalized treatments. Their development of a stem cell model aims to probe the roots of neuroblastoma, a cancer ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers